AcelRx Pharmaceuticals (ACRX) Reports In-Line Q3 Loss of 38c/Share

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.38), in-line with the analyst estimate of ($0.38). Revenue for the quarter came in at $166 thousand versus the consensus estimate of $320 thousand.

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'